Reversing the Trend? The Possibility that Rule Changes May Lead to Fewer Reverse Payments in Pharma Settlements
Anne Layne-Farrar, Nov 01, 2009
This article begins by laying out a simple framework that makes obvious the incentives at play in generic drug entry, brand challenges, and settlements between the two. Once this common understanding has been established, several rule changes that have taken place are summarized one in the form of an amendment to Hatch-Waxman and another in a recent decision by the Court of Appeals for the Federal Circuit. These institutional changes may have the consequence of reducing the prevalence of reverse payments. This possibility suggests a different policy tact might be called for, one that shifts emphasis from determining whether or not reverse payments should be per se illegal to working with the incentives that firms already face and exploiting those incentives to reduce firms inclinations to enter into anticompetitive reverse-payment settlements.
Links to Full Content
Featured News
Plaintiffs Seek Communications In Antitrust Case Against Pioneer
May 9, 2024 by
CPI
UK Government Approves Vodafone-Hutchison Merger
May 9, 2024 by
CPI
Senate Majority Leader Announces Plan for AI Regulation Framework
May 9, 2024 by
CPI
BBVA Initiates Aggressive Takeover Bid for Sabadell
May 9, 2024 by
CPI
TikTok to Label AI-Generated Content Amid Election Interference Concerns
May 9, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI